SCI Abstract

search
+
Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism
Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism
Abstract Aim Clinical evaluations are generally used to verify the effectiveness of detoxification treatments for alcohol ...
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma
Abstract Aim The microRNA (miR) clusters miR-183/96/182 and miR-217/216a/216b are significantly upregulated in nonviral he...
Can microRNA‐96‐5p serve as a therapeutic molecule in the near future?
Can microRNA‐96‐5p serve as a therapeutic molecule in the near future?
Volume 52, Issue 1 p. 3-4 EDITORIAL Tsutomu Masaki, Corresponding Author ...
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)
Abstract In the 22nd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21 155 newly registere...
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis
Abstract Aim Acute-on-chronic liver failure (ACLF) is associated with a high risk of short-term mortality after progressio...
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Abstract Background Atezolizumab plus bevacizumab was approved for hepatocellular carcinoma (HCC) patients in 2020, but tr...
ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR‐548p/TUFT1 axis
ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR‐548p/TUFT1 axis
AbstractAimDue to high invasion and metastasis, hepatocellular carcinoma is known as one of the most fatal carcinomas. We ...
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis
Abstract Aim Direct-acting antivirals (DAAs) are currently available even for patients with decompensated cirrhosis. Repor...
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Abstract Background/Aim Although systemic therapy is recommended for patients with multiple intermediate stage unresectabl...
Factors associated with portopulmonary hypertension
Factors associated with portopulmonary hypertension
PDF ShareShare Please review our Terms and Conditions of Use...
Is it necessary to revise the liver transplantation guidelines to meet the current situation?
Is it necessary to revise the liver transplantation guidelines to meet the current situation?
Volume 51, Issue 12 p. 1177-1178 EDITORIAL Takeshi Matsui, Corresponding Author ...
Unexpected hepatitis B virus transmission after liver transplant from nucleic acid testing‐ and serology‐negative liver donors who are hepatitis C viremic
Unexpected hepatitis B virus transmission after liver transplant from nucleic acid testing‐ and serology‐negative liver donors who are hepatitis C viremic
Abstract The opioid epidemic has led to increased availability of organs for liver transplantation. The success of direct-...
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era
AbstractAimsFibrosis-4 index (FIB-4) and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are the two most w...
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension
ABSTRACT Aim This study aimed to demonstrate the feasibility of identifying candidates of portopulmonary hypertension (PoP...
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV
Abstract Aim After the hepatitis A virus (HAV) outbreak among men who have sex with men (MSM) around 2018, the importance ...
Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C
Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C
Abstract Background Non-invasive tests (NITs), such as Fibrosis-4 index (FIB-4) and the aspartate aminotransferase-to-plat...
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to 7 criteria – multicenter analysis
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to 7 criteria – multicenter analysis
AbstractBackground/AimAlthough systemic therapy is recommended for patients with multiple intermediate stage unresectable ...
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population
Abstract Aim The global burden of chronic liver disease is substantial. Limited studies have reported the prevalence of me...
Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes
Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes
Abstract Aim Curing hepatitis B virus (HBV) infection requires elimination of covalently closed circular DNA (cccDNA). Int...
Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B
Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B
Abstract Background Long-term use of nucleotide analogs such as adefovir (ADV) or tenofovir disoproxil fumarate (TDF) may ...
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: prevalence and associated factors in the middle‐aged and older U.S. population
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: prevalence and associated factors in the middle‐aged and older U.S. population
Abstract Background The global burden of chronic liver disease is substantial. Limited studies have reported the prevalenc...
Proposal for new sleep disorder criteria in patients with chronic liver disease: influence of liver‐related complications
Proposal for new sleep disorder criteria in patients with chronic liver disease: influence of liver‐related complications
AbstractAimSleep disorder is common in patients with chronic liver disease (CLD). Liver-related silent complications, incl...
Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection
Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection
AbstractAimFew reported studies examine the relationship between zinc (Zn) deficiency and short- and long-term outcomes in...
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis
AbstractPurposeTo assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab ...
Development and multicenter validation of FIB‐6; a novel, machine‐learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in CHC patients
Development and multicenter validation of FIB‐6; a novel, machine‐learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in CHC patients
AbstractBackgroundNoninvasive tests (NITs) such as Fibrosis-4 index (FIB-4) and the aspartate aminotransferase to platelet...
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis
Abstract Aim Portal vein thrombosis (PVT) is a major complication in patients with liver cirrhosis (LC). In some cases, PV...
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach
Abstract Aim Metabolic associated fatty liver disease (MAFLD) partly overlaps with non-alcoholic fatty liver disease (NAFL...
Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients
Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients
Volume 51, Issue 11 p. 1170-1171 LETTER TO THE EDITOR Nobuharu Tamaki, Department of ...
MET amplification as a potential therapeutic target against hepatocellular carcinoma
MET amplification as a potential therapeutic target against hepatocellular carcinoma
Volume 51, Issue 11 p. 1093-1094 EDITORIAL Yuji Eso, Corresponding Author ...
Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease
Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease
Volume 51, Issue 11 p. 1172-1173 LETTER TO THE EDITOR Nobuharu Tamaki, Corresponding ...
Load More
format_indent_increase